EUVIMEDEUVIMED entdecken
Open Access

Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality

Sheng Nie iD, Yanqin Li, Yinfang Sun, Shan Chen, Xian Shao iD, Mingzhen Pang, Shiyu Zhou, Licong Su, Ruixuan Chen iD, Fan Luo, Xin Xu iD, Fan Fan Hou iD und 1 weitere

Journal of the American Society of Nephrology · 2025-12 · 36 (12) · 2410-2420

DOI: 10.1681/asn.0000000775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 18.06.2025. Verfasst von Sheng Nie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Na…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key R&D Program of China, Key Technologies R&D Program of Guangdong Province, Guangdong Provincial Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points It is uncertain whether the discontinuation of renin-angiotensin system (RAS) improves prognosis among patients during an episode of hospital-acquired AKI. Discontinuation of RAS inhibitors within 2 days after AKI was associated with lower risk of all-cause mortality as compared with continuation. Temporary discontinuation of RAS inhibitors during AKI episodes may improve outcomes in long-term users.

Background

Renin-angiotensin system inhibitors (RASis) are widely used among patients with cardiovascular disease, diabetes, and CKD, which are high-risk populations for AKI. Evidence for the optimal management of RASi during an episode of AKI is lacking.

Methods

We conducted a multidatabase cohort study using sequential target trial emulation framework from the China Renal Data System and Medical Information Mart for Intensive Care IV (MIMIC-IV) databases. Adult patients with hospital-acquired AKI who had been receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers treatment for at least 90 days were included. The primary outcomes were 30- and 180-day all-cause mortality. Adjusted cumulative incidences and risk differences were estimated using weighted pooled logistic regression models.

Results

A total of 27,003 person-trials were identified from the China Renal Data System database (median [interquartile range] age, 70 [58–78] years; 12,972 [60%] male) and the MIMIC-IV database (median [interquartile range] age, 73 [63–82] years; 2825 [53%] male). The adjusted cumulative incidence of 30-day all-cause mortality was lower among person-trials with RASi discontinuation within 2 days after the hospital-acquired AKI than continuation (4.36% versus 5.91%), with a risk difference of −1.55% (95% confidence interval, −2.43% to −0.55%). Discontinuation of RASi was consistently associated with lower risk of all-cause mortality in the MIMIC-IV database, with similar beneficial associations observed across stratified analyses and multiple sensitivity analyses.

Conclusions

In this study, stopping RASi within the first 2 days of AKI detection was associated with a lower risk of all-cause mortality.

Schlagwörter

Stichwörter der Autor:innen

ACE inhibitorsAKIAKI and critical caremortality

Autor:innen und Institutionen

  • Division of Nephrology, State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Sheng Nie, Xian Shao, Ruixuan Chen, Xin Xu, Fan Fan Hou

Förderung

  • National Key R&D Program of China
  • Key Technologies R&D Program of Guangdong Province
  • Guangdong Provincial Clinical Research
  • Program of Introducing Talents of Discipline to Universities
  • National Natural Science Foundation of China

Zitieren

APA

Nie, S., Li, Y., Sun, Y., Chen, S., Shao, X., Pang, M., Zhou, S., Su, L., Chen, R., Luo, F., Xu, X., Hou, F. F., & CRDS Study Investigators (2025). Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality. Journal of the American Society of Nephrology, 36(12), 2410-2420. https://doi.org/10.1681/asn.0000000775

Vancouver

Nie S, Li Y, Sun Y, Chen S, Shao X, Pang M, et al. Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality. Journal of the American Society of Nephrology. 2025;36(12):2410-2420. doi:10.1681/asn.0000000775

BibTeX
@article{Nie2025,
  author = {Nie, Sheng and Li, Yanqin and Sun, Yinfang and Chen, Shan and Shao, Xian and Pang, Mingzhen and Zhou, Shiyu and Su, Licong and Chen, Ruixuan and Luo, Fan and Xu, Xin and Hou, Fan Fan and CRDS Study Investigators, CRDS Study Investigators},
  title = {Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality},
  journal = {Journal of the American Society of Nephrology},
  year = {2025},
  volume = {36},
  number = {12},
  pages = {2410--2420},
  doi = {10.1681/asn.0000000775}
}
Kostenlos starten →